Maiwei Biopharma: Marketing Authorization Application for 9MW0813 Injection Accepted

2025-09-19 15:40:54

Maiwei Biopharma announced that it recently received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for its marketing authorization application (MAA) for 9MW0813 Injection, intended for the treatment of diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). 9MW0813 Injection, a biosimilar to aflibercept (Aylea®), is a recombinant fusion protein formed by the extracellular binding domains of VEGFR-1 and VEGFR-2, combined with the Fc region of a human immunoglobulin. It binds to VEGF-A and PlGF.

AMD

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    Alipay's two operating entities have completed the name change
                            2025-09-19

                                    Hande Information: The company has cooperation with Oracle
                            2025-09-23